Assessment and Management of Post-Stroke Spasticity With Botulinum Toxin-A


Phase N/A Results N/A

Summary of Purpose

Within the first year after stroke, approximately 38% of stroke survivors experience an increased resistance to movement, also called spasticity. One type of treatment that is approved for stroke survivors in Canada that could reduce spasticity is the injection of Botulinum toxin (BTX) into the affected muscle. While BTX reduces spasticity, there is limited evidence to show that BTX administration leads to...

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 19 May 2015.

1 May 2011 13 Dec 2012 1 Nov 2014 1 Nov 2014 1 May 2015 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Design

  • Allocation: Randomized
  • Masking: Single Blind (Investigator)
  • Purpose: Treatment
  • Endpoint: Efficacy Study
  • Intervention: Crossover Assignment